Trial Outcomes & Findings for Expression of Longevity Genes in Response to Extended Fasting (NCT NCT01059760)

NCT ID: NCT01059760

Last Updated: 2017-07-17

Results Overview

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

30 participants

Primary outcome timeframe

Baseline and 3 days

Results posted on

2017-07-17

Participant Flow

Participant milestones

Participant milestones
Measure
Fasting Day First
28±4 hours of water-only fasting followed by 28±4 hours fed
Fed Day First
28± 4 hours fed followed by 28± 4 hours of fasting
Overall Study
STARTED
16
14
Overall Study
COMPLETED
16
14
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Expression of Longevity Genes in Response to Extended Fasting

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Fasting Day First
n=16 Participants
28±4 hours of water-only fasting followed by 28±4 hours fed
Fed Day First
n=14 Participants
28± 4 hours fed followed by 28± 4 hours of fasting
Total
n=30 Participants
Total of all reporting groups
Age, Continuous
43.3 years
STANDARD_DEVIATION 13.6 • n=5 Participants
44.0 years
STANDARD_DEVIATION 14.0 • n=7 Participants
43.6 years
STANDARD_DEVIATION 13.5 • n=5 Participants
Sex: Female, Male
Female
11 Participants
n=5 Participants
9 Participants
n=7 Participants
20 Participants
n=5 Participants
Sex: Female, Male
Male
5 Participants
n=5 Participants
5 Participants
n=7 Participants
10 Participants
n=5 Participants
Region of Enrollment
United States
16 participants
n=5 Participants
14 participants
n=7 Participants
30 participants
n=5 Participants
Body Mass Index (BMI)
28.4 kg/m^2
STANDARD_DEVIATION 7.1 • n=5 Participants
27.3 kg/m^2
STANDARD_DEVIATION 6.1 • n=7 Participants
27.8 kg/m^2
STANDARD_DEVIATION 1.3 • n=5 Participants
Hemoglobin A1C
5.5 percentage
STANDARD_DEVIATION 0.3 • n=5 Participants
5.3 percentage
STANDARD_DEVIATION 0.3 • n=7 Participants
5.4 percentage
STANDARD_DEVIATION 0.3 • n=5 Participants

PRIMARY outcome

Timeframe: Baseline and 3 days

Outcome measures

Outcome measures
Measure
Baseline Value
n=30 Participants
Change While Fasting
n=30 Participants
Change When Fed
n=30 Participants
Change From Baseline in Participant Glucose When Fasting and Fed
83.3 mg/dL
Standard Deviation 15.8
-8.0 mg/dL
Standard Deviation 15.4
5.9 mg/dL
Standard Deviation 16.6

PRIMARY outcome

Timeframe: Baseline and 3 days

Outcome measures

Outcome measures
Measure
Baseline Value
n=30 Participants
Change While Fasting
n=30 Participants
Change When Fed
n=30 Participants
Change From Baseline in Participant Human Growth Hormone (HGH) When Fasting and Fed
0.32 ng/mL
Standard Deviation 0.47
1.54 ng/mL
Standard Deviation 2.63
-1.14 ng/mL
Standard Deviation 1.66

PRIMARY outcome

Timeframe: Baseline and 3 days

Outcome measures

Outcome measures
Measure
Baseline Value
n=30 Participants
Change While Fasting
n=30 Participants
Change When Fed
n=30 Participants
Change From Baseline in Participant Insulin When Fasting and Fed
23.6 mU/L
Standard Deviation 17.8
-19.0 mU/L
Standard Deviation 29.3
-1.6 mU/L
Standard Deviation 16.2

PRIMARY outcome

Timeframe: Baseline and 3 days

HOMA-IR is used to measure the severity of insulin resistance. Healthy Range: 1.0 (0.5-1.4) Less than 1.0 is optimal Above 1.9 indicates early insulin resistance Above 2.9 indicates significant insulin resistance

Outcome measures

Outcome measures
Measure
Baseline Value
n=30 Participants
Change While Fasting
n=30 Participants
Change When Fed
n=30 Participants
Change From Baseline in Participant Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) When Fasting and Fed
0.66 units on a scale
Standard Deviation 0.051
-0.35 units on a scale
Standard Deviation 0.53
-.02 units on a scale
Standard Deviation 0.30

PRIMARY outcome

Timeframe: Baseline and 3 days

Outcome measures

Outcome measures
Measure
Baseline Value
n=30 Participants
Change While Fasting
n=30 Participants
Change When Fed
n=30 Participants
Change From Baseline in Participant Glycogen-Like Protein-1 (GLP-1) When Fasting and Fed
1.77 ng/mL
Standard Deviation 0.79
-0.27 ng/mL
Standard Deviation 0.51
0.07 ng/mL
Standard Deviation 0.51

PRIMARY outcome

Timeframe: Baseline and 3 days

Outcome measures

Outcome measures
Measure
Baseline Value
n=30 Participants
Change While Fasting
n=30 Participants
Change When Fed
n=30 Participants
Change From Baseline in Participant Adiponectin When Fasting and Fed
0.34 ratio of high molecular to total
Standard Deviation 0.17
0.02 ratio of high molecular to total
Standard Deviation 0.25
-0.07 ratio of high molecular to total
Standard Deviation 0.25

PRIMARY outcome

Timeframe: Baseline and 3 days

Outcome measures

Outcome measures
Measure
Baseline Value
n=30 Participants
Change While Fasting
n=30 Participants
Change When Fed
n=30 Participants
Change From Baseline in Participant Fibroblast Growth Factor-21 (FGF-21) When Fasting and Fed
190.3 pg/mL
Standard Deviation 261.4
-41.7 pg/mL
Standard Deviation 128.9
9.5 pg/mL
Standard Deviation 108.8

PRIMARY outcome

Timeframe: Baseline and 3 days

Outcome measures

Outcome measures
Measure
Baseline Value
n=30 Participants
Change While Fasting
n=30 Participants
Change When Fed
n=30 Participants
Change From Baseline in Participant White Blood Cell Count (WBC) When Fasting and Fed
6.0 cells/mL
Standard Deviation 1.4
0.32 cells/mL
Standard Deviation 1.31
-0.12 cells/mL
Standard Deviation 1.48

PRIMARY outcome

Timeframe: Baseline and 3 days

Outcome measures

Outcome measures
Measure
Baseline Value
n=30 Participants
Change While Fasting
n=30 Participants
Change When Fed
n=30 Participants
Change From Baseline in Participant Hemoglobin When Fasting and Fed
14.3 g/dL
Standard Deviation 1.3
0.46 g/dL
Standard Deviation 0.37
-0.39 g/dL
Standard Deviation 0.52

PRIMARY outcome

Timeframe: Baseline and 3 days

Outcome measures

Outcome measures
Measure
Baseline Value
n=30 Participants
Change While Fasting
n=30 Participants
Change When Fed
n=30 Participants
Change From Baseline in Participant Red Blood Cell Count (RBC) When Fasting and Fed
4.7 cells x 10^6/mL
Standard Deviation 0.4
0.15 cells x 10^6/mL
Standard Deviation 0.13
-0.11 cells x 10^6/mL
Standard Deviation 0.17

PRIMARY outcome

Timeframe: Baseline and 3 days

Outcome measures

Outcome measures
Measure
Baseline Value
n=30 Participants
Change While Fasting
n=30 Participants
Change When Fed
n=30 Participants
Change From Baseline in Participant Hematocrit When Fasting and Fed
41.6 % of red blood cells to whole blood
Standard Deviation 3.6
1.3 % of red blood cells to whole blood
Standard Deviation 1.3
-1.1 % of red blood cells to whole blood
Standard Deviation 1.5

PRIMARY outcome

Timeframe: Baseline and 3 days

Outcome measures

Outcome measures
Measure
Baseline Value
n=30 Participants
Change While Fasting
n=30 Participants
Change When Fed
n=30 Participants
Change From Baseline in Participant Platelet Count When Fasting and Fed
253.5 cells x 10^3/mL
Standard Deviation 58.2
2.8 cells x 10^3/mL
Standard Deviation 16.3
0.9 cells x 10^3/mL
Standard Deviation 13.8

PRIMARY outcome

Timeframe: Baseline and 3 days

Outcome measures

Outcome measures
Measure
Baseline Value
n=30 Participants
Change While Fasting
n=30 Participants
Change When Fed
n=30 Participants
Change From Baseline in Participant Mean Corpuscular Volume (MCV) When Fasting and Fed
89.11 fL
Standard Deviation 3.56
-0.12 fL
Standard Deviation 0.68
-0.18 fL
Standard Deviation 0.73

PRIMARY outcome

Timeframe: Baseline and 3 days

Outcome measures

Outcome measures
Measure
Baseline Value
n=30 Participants
Change While Fasting
n=30 Participants
Change When Fed
n=30 Participants
Change From Baseline in Participant Mean Corpuscular Hemoglobin (MCH) When Fasting and Fed
30.66 pg
Standard Deviation 1.48
-0.01 pg
Standard Deviation 0.33
-0.07 pg
Standard Deviation 0.40

PRIMARY outcome

Timeframe: Baseline and 3 days

Outcome measures

Outcome measures
Measure
Baseline Value
n=30 Participants
Change While Fasting
n=30 Participants
Change When Fed
n=30 Participants
Change From Baseline in Participant Mean Corpuscular Hemoglobin Concentration (MCHC) When Fasting and Fed
34.4 g/dL
Standard Deviation 0.5
0.02 g/dL
Standard Deviation 0.49
-0.01 g/dL
Standard Deviation 0.52

PRIMARY outcome

Timeframe: Baseline and 3 days

Outcome measures

Outcome measures
Measure
Baseline Value
n=30 Participants
Change While Fasting
n=30 Participants
Change When Fed
n=30 Participants
Change From Baseline in Participant Red Cell Distribution Width (RDW) When Fasting and Fed
13.6 % of SD of MCV to mean MCV
Standard Deviation 0.82
-0.04 % of SD of MCV to mean MCV
Standard Deviation 0.32
-0.03 % of SD of MCV to mean MCV
Standard Deviation 0.37

PRIMARY outcome

Timeframe: Baseline and 3 days

Outcome measures

Outcome measures
Measure
Baseline Value
n=30 Participants
Change While Fasting
n=30 Participants
Change When Fed
n=30 Participants
Change From Baseline in Participant Mean Platelet Volume (MPV) When Fasting and Fed
8.17 fL
Standard Deviation 0.83
0.02 fL
Standard Deviation 0.49
0.03 fL
Standard Deviation 0.26

PRIMARY outcome

Timeframe: Baseline and 3 days

Outcome measures

Outcome measures
Measure
Baseline Value
n=30 Participants
Change While Fasting
n=30 Participants
Change When Fed
n=30 Participants
Change From Baseline in Participant Bicarbonate When Fasting and Fed
27.0 mmol/L
Standard Deviation 2.5
-1.4 mmol/L
Standard Deviation 1.7
0.9 mmol/L
Standard Deviation 2.2

PRIMARY outcome

Timeframe: Baseline and 3 days

Outcome measures

Outcome measures
Measure
Baseline Value
n=30 Participants
Change While Fasting
n=30 Participants
Change When Fed
n=30 Participants
Change From Baseline in Participant Sodium When Fasting and Fed
139.1 mmol/L
Standard Deviation 2.0
-1.4 mmol/L
Standard Deviation 2.1
0.7 mmol/L
Standard Deviation 2.0

PRIMARY outcome

Timeframe: Baseline and 3 days

Outcome measures

Outcome measures
Measure
Baseline Value
n=30 Participants
Change While Fasting
n=30 Participants
Change When Fed
n=30 Participants
Change From Baseline in Participant Chloride When Fasting and Fed
103.7 mmol/L
Standard Deviation 2.7
-1.3 mmol/L
Standard Deviation 2.0
0.9 mmol/L
Standard Deviation 2.3

PRIMARY outcome

Timeframe: Baseline and 3 days

Outcome measures

Outcome measures
Measure
Baseline Value
n=30 Participants
Change While Fasting
n=30 Participants
Change When Fed
n=30 Participants
Change From Baseline in Participant Blood Urea Nitrogen (BUN) When Fasting and Fed
16.0 mg/dL
Standard Deviation 3.7
-1.2 mg/dL
Standard Deviation 3.9
1.8 mg/dL
Standard Deviation 2.6

PRIMARY outcome

Timeframe: Baseline and 3 days

Outcome measures

Outcome measures
Measure
Baseline Value
n=30 Participants
Change While Fasting
n=30 Participants
Change When Fed
n=30 Participants
Change From Baseline in Participant Calcium When Fasting and Fed
9.4 mg/dL
Standard Deviation 0.3
0.18 mg/dL
Standard Deviation 0.34
-0.12 mg/dL
Standard Deviation 0.33

PRIMARY outcome

Timeframe: Baseline and 3 days

Outcome measures

Outcome measures
Measure
Baseline Value
n=30 Participants
Change While Fasting
n=30 Participants
Change When Fed
n=30 Participants
Change From Baseline in Participant Potassium When Fasting and Fed
4.29 mmol/L
Standard Deviation 0.28
-0.02 mmol/L
Standard Deviation 0.30
0.02 mmol/L
Standard Deviation 0.32

PRIMARY outcome

Timeframe: Baseline and 3 days

Outcome measures

Outcome measures
Measure
Baseline Value
n=30 Participants
Change While Fasting
n=30 Participants
Change When Fed
n=30 Participants
Change From Baseline in Participant Creatinine When Fasting and Fed
0.848 mg/dL
Standard Deviation 0.118
0.005 mg/dL
Standard Deviation 0.09
0.002 mg/dL
Standard Deviation 0.06

PRIMARY outcome

Timeframe: Baseline and 3 days

Outcome measures

Outcome measures
Measure
Baseline Value
n=30 Participants
Change While Fasting
n=30 Participants
Change When Fed
n=30 Participants
Change From Baseline in Participant Total Cholesterol (TC) When Fasting and Fed
190.7 mg/dL
Standard Deviation 30.7
9.5 mg/dL
Standard Deviation 10.6
-4.8 mg/dL
Standard Deviation 11.0

PRIMARY outcome

Timeframe: Baseline and 3 days

Outcome measures

Outcome measures
Measure
Baseline Value
n=30 Participants
Change While Fasting
n=30 Participants
Change When Fed
n=30 Participants
Change From Baseline in Participant Low-Density Lipoprotein Cholesterol (LDL-C) When Fasting and Fed
103.8 mg/dL
Standard Deviation 33.8
23.1 mg/dL
Standard Deviation 35.1
-10.3 mg/dL
Standard Deviation 28.2

PRIMARY outcome

Timeframe: Baseline and 3 days

Outcome measures

Outcome measures
Measure
Baseline Value
n=30 Participants
Change While Fasting
n=30 Participants
Change When Fed
n=30 Participants
Change From Baseline in Participant High-Density Lipoprotein Cholesterol (HDL-C) When Fasting and Fed
55.9 mg/dL
Standard Deviation 14.3
3.7 mg/dL
Standard Deviation 5.3
-1.0 mg/dL
Standard Deviation 3.6

PRIMARY outcome

Timeframe: Baseline and 3 days

Outcome measures

Outcome measures
Measure
Baseline Value
n=30 Participants
Change While Fasting
n=30 Participants
Change When Fed
n=30 Participants
Change From Baseline in Participant Triglycerides When Fasting and Fed
134.2 mg/dL
Standard Deviation 77.0
-52.4 mg/dL
Standard Deviation 55.5
11.2 mg/dL
Standard Deviation 38.1

PRIMARY outcome

Timeframe: Baseline and 3 days

Outcome measures

Outcome measures
Measure
Baseline Value
n=30 Participants
Change While Fasting
n=30 Participants
Change When Fed
n=30 Participants
Change From Baseline in Participant TC/HDL Ratio When Fasting and Fed
3.63 ratio
Standard Deviation 1.15
-3.3 ratio
Standard Deviation 17.7
0.0 ratio
Standard Deviation 0.2

PRIMARY outcome

Timeframe: Baseline and 3 days

Outcome measures

Outcome measures
Measure
Baseline Value
n=30 Participants
Change While Fasting
n=30 Participants
Change When Fed
n=30 Participants
Change From Baseline in Participant Weight When Fasting and Fed
81.3 kg
Standard Deviation 25.0
-1.5 kg
Standard Deviation 0.9
0.5 kg
Standard Deviation 0.9

PRIMARY outcome

Timeframe: Baseline and 3 days

Outcome measures

Outcome measures
Measure
Baseline Value
n=30 Participants
Change While Fasting
n=30 Participants
Change When Fed
n=30 Participants
Change From Baseline in Participant Waist Circumference When Fasting and Fed
86.7 cm
Standard Deviation 16.7
-0.57 cm
Standard Deviation 1.4
0.54 cm
Standard Deviation 3.0

PRIMARY outcome

Timeframe: Baseline and 3 days

Outcome measures

Outcome measures
Measure
Baseline Value
n=30 Participants
Change While Fasting
n=30 Participants
Change When Fed
n=30 Participants
Change From Baseline in Participant Systolic Blood Pressure (SBP), Supine When Fasting and Fed
114.0 mmHg
Standard Deviation 13.6
-3.1 mmHg
Standard Deviation 8.4
1.0 mmHg
Standard Deviation 9.6

PRIMARY outcome

Timeframe: Baseline and 3 days

Outcome measures

Outcome measures
Measure
Baseline Value
n=30 Participants
Change While Fasting
n=30 Participants
Change When Fed
n=30 Participants
Change From Baseline in Participant Diastolic Blood Pressure (DBP), Supine When Fasting and Fed
67.2 mmHg
Standard Deviation 8.8
1.7 mmHg
Standard Deviation 7.4
-1.2 mmHg
Standard Deviation 8.9

PRIMARY outcome

Timeframe: Baseline and 3 days

Outcome measures

Outcome measures
Measure
Baseline Value
n=30 Participants
Change While Fasting
n=30 Participants
Change When Fed
n=30 Participants
Change From Baseline in Participant High Sensitivity C-Reactive Protein (hsCRP) When Fasting and Fed
1.35 mg/L
Standard Error 0.96
0.00 mg/L
Standard Error 0.44
-0.10 mg/L
Standard Error 0.24

Adverse Events

Fasting Day First

Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths

Fed Day First

Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Fasting Day First
n=16 participants at risk
Includes those who fasted on the 1st day.
Fed Day First
n=14 participants at risk
Includes those who fasted on the 2nd day.
General disorders
Mild Headache
6.2%
1/16 • Number of events 1 • 3 days
7.1%
1/14 • Number of events 1 • 3 days
General disorders
Migraine
6.2%
1/16 • Number of events 1 • 3 days
0.00%
0/14 • 3 days

Additional Information

Benjamin D. Horne

Intermountain Heart Institute

Phone: 8015074708

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place